Experts Warn Hepatitis B Treatment Too Complex; Philippines Faces High Burden

Hepatitis B prevention and treatment face persistent obstacles, from high prevalence in endemic regions to overly complex clinical guidelines that may discourage frontline providers from managing the disease.

In the Philippines, one of the most hepatitis B-endemic countries in the Western Pacific, an estimated 7.3 million adult Filipinos—approximately 17% of the adult population—are living with chronic hepatitis B, according to the Hepatology Society of the Philippines. This is more than double the regional average. Globally, viral hepatitis claims more than a million lives annually, primarily from liver cirrhosis and liver cancer.

While there is no specific treatment for acute hepatitis B, chronic infection can be managed with antiviral medications that suppress viral replication, slow disease progression, significantly reduce liver cancer risk, and improve long-term survival. However, experts argue that the complexity of treatment algorithms and restrictive historical criteria may have unintentionally signaled to primary care clinicians that hepatitis B care should be left to specialists.

During a recent panel discussion, hepatologists explored whether the field has created a form of paternalism toward other clinicians, making them hesitant to initiate therapy for fear of doing something wrong. A physician living with chronic hepatitis B shared that many clinicians were uncomfortable discussing treatment outside strict guideline thresholds, even as some privately admitted they would choose therapy for themselves. Patients, she noted, often question why safe, effective, and increasingly affordable medications are withheld when the benefits of early intervention could be substantial.

Emerging research on viral DNA integration, immune exhaustion, and long-term oncogenic risk continues to reshape understanding of disease progression, but this mechanistic science does not easily fit into the evidence frameworks used to generate formal recommendations. The disconnect may contribute to a gap between how experts perceive risk and how treatment decisions are communicated in practice. Empowering primary care providers to feel comfortable managing hepatitis B is essential to expanding access, experts agreed, emphasizing that care should not remain confined to specialist settings.

Vaccination remains the most powerful tool against hepatitis B. The World Health Organization states that the vaccine provides protection for at least 20 years and likely for life; it was also the first vaccine proven to prevent a major human cancer. In the Philippines, perinatal transmission is a leading cause of infection, and the Department of Health mandates a birth dose of the hepatitis B vaccine within 24 hours of life, followed by the complete series under the Expanded Program on Immunization. Pregnant women diagnosed with chronic hepatitis B may also receive antiviral therapy to reduce transmission risk.

Thailand’s experience demonstrates what can be achieved through sustained public health commitment. After introducing universal newborn vaccination in 1992, combined with routine screening of pregnant women and timely immunoglobulin administration, hepatitis B carrier rates among children under 10 dropped to below 0.1%—meeting the WHO target for eliminating mother-to-child transmission. Older populations continue to be actively screened and linked to care, moving the country closer to the 2030 elimination goal. Such comprehensive approaches, along with efforts to simplify treatment guidelines, are seen as critical to reducing the global burden of hepatitis B.